Filing Details

Accession Number:
0001213900-19-005843
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-04-05 16:06:19
Reporting Period:
2019-04-03
Accepted Time:
2019-04-05 16:06:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1506251 Citius Pharmaceuticals Inc. CTXR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1199080 Z Myron Holubiak C/O Citius Pharmaceuticals, Inc.
11 Commerce Drive, 1St Floor
Cranford NJ 07016
President And Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-04-03 129,450 $1.55 1,433,646 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant to Purchase Common Stock Acquisiton 2019-04-03 129,450 $0.00 129,450 $1.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
129,450 2021-04-05 No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Warrant to Purchase Common Stock $1.15 2023-08-14 784,314 784,314 Direct
Common Stock Options to Purchase Common Stock $8.10 2025-10-01 26,667 26,667 Direct
Common Stock Options to Purchase Common Stock $3.45 2027-09-13 40,000 40,000 Direct
Common Stock Warrant to Purchase Common Stock $6.21 2019-06-12 19,615 19,615 Direct
Common Stock Options to Purchase Common Stock $1.62 2028-09-04 150,000 150,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2023-08-14 784,314 784,314 Direct
2025-10-01 26,667 26,667 Direct
2027-09-13 40,000 40,000 Direct
2019-06-12 19,615 19,615 Direct
2028-09-04 150,000 150,000 Direct
Footnotes
  1. The warrant is fully vested and exercisable immediately.
  2. The purchase price of the warrants was included in the purchase price of the common stock reported in Table I.
  3. The option granted vested and became exercisable as follows: the option to purchase 2,667 shares of common stock of the Company (the "Common Stock") vested on October 1, 2015, and the balance of the option to purchase shares of Common Stock vested in twelve (12) equal installments commencing on December 31, 2015.
  4. One-third of the shares of the Company's common stock underlying the grant vest on the first anniversary of the vesting commencement date, September 13, 2018. The remaining shares of the Company's common stock underlying the grant vest in equal monthly installments at the end of each month for two years following the initial vest.
  5. One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date.